Morphic Therapeutic
Waltham
About Morphic Therapeutic
Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. The company offers the development of therapies for patients with immunological, fibrotic, neoplastic, and vascular diseases, focusing on creating small molecule inhibitors of various integrin targets.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $50K – $100K
- Total funding: $510.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (May 2023)
- Ticker: nasdaq:MORF
- Website: morphictx.com
- Phone: (781)996-0955
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/morphic-therapeutic-141012 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.